MD News (press release)Early PET Predicts Survival Outcomes in B-Cell LymphomaMD News (press release)An interim [ 18 F] fluorodeoxyglucose positron emission tomography can effectively predict the survival outcomes of patients with diffuse large B-cell …
MD NewsEarly PET Predicts Survival Outcomes in B-Cell LymphomaDoctors LoungeAn interim [ 18 F] fluorodeoxyglucose positron emission tomography can effectively predict the survival outcomes of patients with diffuse large B-cell lymphoma after two cycles…
REVLIMID(R) Evaluated in Combination with Rituximab as a Potential Treatment …MarketWatch (press release)The multicenter phase II study enrolled 69 patients and evaluated the efficacy and safety of combination therapy with lenalidomide and rituximab …
ASH: Obinutuzumab Bests Rituximab in Patients With Relapsed Non-Hodgkin LymphomaCancer NetworkSAN DIEGO—Obinutuzumab (GA101) achieved higher response rates than rituximab in the first head-to-head trial of the two biologic agents in patients with rel…
BiovaxID(R) Lymphoma Vaccine-Induced T-Cell Immune Responses Complement …MarketWatch (press release)The results (detailed in Abstract #2707), reported by a Senior Investigator from the NCI, demonstrated that vaccination with BiovaxID active immunothe…
Abbott Labs Spinoff Looks Like the Right MoveInvestorplace.comAlso in development is daclizumab, which appears to be both safe and effective in treating the most common form of multiple sclerosis. Phase III testing is also underway for bardoxolone, whi…
Roche's blood cancer antibody outperforms MabTheraPMLiVERoche says it will now press on with phase III testing of GA101 as an alternative to MabThera (rituximab), which was originated by Biogen Idec and is sold by Roche outside the USA and Japan. T…
Obinutuzumab: New Drug to Replace Rituximab?MedscapeDecember 12, 2011 (San Diego, California) — For more than a decade now, rituximab (Rituxan, Genentech) has reigned supreme as the only drug of its kind — a monoclonal antibody specifically targeti…
Benefit of Romiplostim vs. Standard of Care (SOC) and SOC+Rituximab in …Monthly Prescribing ReferenceEleven of 16 patients in the SOC arm received rituximab 219–363mg/m 2 once weekly for four weeks. In this post hoc, non-randomized comparison, inve…
Effective Response Rates of Lenalidomide and Rituximab as Initial Treatment of …Monthly Prescribing ReferenceSAN DIEGO, CA—Investigators at the 53 rd American Society of Hematology Annual Meeting and Exposition presented study data demonstrating hi…